CFO
GILD icon

CVA Family Office’s Gilead Sciences GILD Stock Holding History

CVA Family Office’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Sell
2,502
-598
-19% -$78.8K 0.03% 259
2026
Q1 		$432K Buy
3,100
+706
+29% +$98.9K 0.05% 197
2025
Q4 		$294K Buy
2,394
+5
+0.2% +$608 0.03% 241
2025
Q3 		$265K Sell
2,389
-42
-2% -$4.77K 0.03% 246
2025
Q2 		$270K Buy
2,431
+79
+3% +$8.41K 0.04% 244
2025
Q1 		$264K Buy
2,352
+29
+1% +$2.99K 0.04% 238
2024
Q4 		$215K Buy
2,323
+760
+49% +$68.4K 0.03% 263
2024
Q3 		$131K Buy
1,563
+157
+11% +$12K 0.02% 325
2024
Q2 		$96.5K Sell
1,406
-175
-11% -$11.7K 0.02% 363
2024
Q1 		$116K Sell
1,581
-232
-13% -$17.8K 0.02% 335
2023
Q4 		$147K Buy
+1,813
New +$141K 0.03% 275
2023
Q3 		– Sell
-1,448
Closed -$112K – 520
2023
Q2 		$112K Buy
1,448
+60
+4% +$4.79K 0.02% 294
2023
Q1 		$115K Sell
1,388
-39
-3% -$3.23K 0.03% 285
2022
Q4 		$123K Buy
1,427
+85
+6% +$6.73K 0.03% 265
2022
Q3 		$83K Buy
1,342
+475
+55% +$30K 0.02% 268
2022
Q2 		$54K Buy
867
+845
+3,841% +$52.3K 0.01% 355
2022
Q1 		$1K Sell
22
-1,014
-98% -$64.8K ﹤0.01% 920
2021
Q4 		$75K Sell
1,036
-184
-15% -$12.7K 0.02% 290
2021
Q3 		$77K Buy
1,220
+99
+9% +$6.96K 0.06% 138
2021
Q2 		$77K Buy
1,121
+245
+28% +$16.4K 0.02% 285
2021
Q1 		$57K Buy
876
+355
+68% +$22.9K 0.02% 263
2020
Q4 		$30K Sell
521
-699
-57% -$42.2K 0.02% 237
2020
Q3 		$77K Buy
1,220
+100
+9% +$6.93K 0.06% 138
2020
Q2 		$86K Buy
1,120
+920
+460% +$70.5K 0.07% 124
2020
Q1 		$15K Buy
+200
New +$13.8K 0.02% 215

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CVA Family Office's GILD Position: Q2 2026 in Review

CVA Family Office reduced its Gilead Sciences (GILD) stake by 19% in Q2 2026, selling an estimated $78.8K and leaving 2,502 shares worth $316K. The position accounts for 0.03% of the portfolio, ranked #259.

CVA Family Office first reported a position in GILD in Q1 2020 and has held it in 25 quarters since. The position peaked at $432K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • CVA Family Office held 2,502 shares of Gilead Sciences worth $316K as of Q2 2026.
  • CVA Family Office sold 598 Gilead Sciences shares in Q2 2026, an estimated $78.8K.
  • Gilead Sciences made up 0.03% of CVA Family Office's portfolio in Q2 2026, its #259 holding.
  • CVA Family Office first reported a position in Gilead Sciences in Q1 2020 and has held it in 25 quarters since.
  • CVA Family Office's Gilead Sciences position peaked at $432K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.